Genscript Biotech Corporation

As of December 31, 2025, Genscript Biotech Corp carries a market capitalization of 3.64B, placing it among publicly traded companies globally. Its enterprise value stands at 3.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Genscript Biotech Corp's next confirmed earnings release is scheduled for March 24, 2027.

As of December 31, 2025, Genscript Biotech Corp has 2.18B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Genscript Biotech Corp maintains a current ratio of 1.50, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 16, 2026, Genscript Biotech Corp's stock has gained approximately 94.19% over the past 52 weeks. The 50-day moving average sits at 3.68, while the 200-day moving average is 2.56.

As of December 31, 2025, Genscript Biotech Corp holds 811.99M in cash and equivalents against 258.84M in total debt, resulting in a net debt position of 52.18M. Total book value stands at 3.96B, with working capital of 358.80M providing operational flexibility.